DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00502294 (ClinicalTrials.gov)	January 2007	13/7/2007	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis	Intravenous Steroid-Refractory Ulcerative Colitis	Drug: Visilizumab (HuM291; Nuvion®)	Facet Biotech	PDL BioPharma, Inc.	Withdrawn	18 Years	N/A	Both	150	Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00502294
(ClinicalTrials.gov)

January 2007

13/7/2007

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Intravenous Steroid-Refractory Ulcerative Colitis

Drug: Visilizumab (HuM291; Nuvion®)

Facet Biotech

PDL BioPharma, Inc.

Withdrawn

18 Years

N/A

Both

150

Phase 3

NULL